On August 6, GENSCRIPT BIO rose 5.07% in regular trading, trading at 19.67 HKD/share, with turnover of HKD 205 million.

On the news front, the company's associate Legend Biotech disclosed that CARVYKTI generated net trade sales of approximately USD 657 million for the quarter ended June 30, representing nearly 50% year-over-year growth and sustaining strong commercial momentum. The sales data was provided by collaboration partner Janssen Biotech under their cooperation and license agreement.

Additionally, the CXO sector has rallied broadly in recent sessions, buoyed by WuXi AppTec's H1 results showing revenue growth of approximately 39% and non-GAAP net profit growth of approximately 89%, lifting sector sentiment. GENSCRIPT BIO benefits from both industry tailwinds and its own fundamental catalysts. The company's board is scheduled to convene on August 15 to review and approve interim results for H1 and consider an interim dividend.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)